The first ctDNA liquid biopsy approved for use in clinical settings was in lung cancer patients for the identification of EGFR mutations for first-line therapy or identifying resistance mutations that will allow for treatment with third generation EGFR inhibitors [23, 24]. Here, EGFR is linked to lung carcinoma.